Suppr超能文献

一项关于水痘疫苗接种失败与哮喘、类固醇使用、接种年龄以及麻疹-腮腺炎-风疹疫苗接种之间关联的回顾性队列研究。

A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination.

作者信息

Verstraeten Thomas, Jumaan Aisha O, Mullooly John P, Seward Jane F, Izurieta Hector S, DeStefano Frank, Black Steven B, Chen Robert T

机构信息

Epidemic Intelligence Service Program, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

出版信息

Pediatrics. 2003 Aug;112(2):e98-103. doi: 10.1542/peds.112.2.e98.

Abstract

OBJECTIVE

Varicella breakthrough, the occurrence of varicella disease >42 days after vaccination, is indicative of vaccination failure. A sevenfold increased risk of breakthrough among vaccinated children with asthma was observed in a 1996 varicella outbreak in a child care center. More recent outbreak investigations have also identified age at vaccination as a potential risk factor for breakthrough. We assessed the association of varicella breakthrough with asthma, steroids, age at varicella vaccination, and timing of measles-mumps-rubella (MMR) vaccination.

METHODS

We performed a retrospective cohort study among children born after 1993 and followed up through 1999 at 2 health maintenance organizations ([HMOs] A and B) in the United States. Information was obtained from automated vaccination, clinic, hospital discharge, and pharmacy records.

RESULTS

We identified 268 and 97 breakthrough cases among 80 584 and 8181 children vaccinated against varicella at HMOs A and B, respectively. Varicella breakthrough was not associated with asthma, inhaled steroids prescribed at any time, and oral steroids prescribed before vaccination. An increased risk of varicella breakthrough was found in the 3 months immediately after prescription for oral steroids at HMO A (adjusted relative risk [aRR]: 2.4; 95% confidence interval [CI]: 1.3-4.4) and HMO B (aRR: 2.8; 95% CI: 1.0-7.8), when varicella vaccine was given before 15 months of age at HMO A (aRR: 1.4; 95% CI: 1.1-1.9), and when varicella vaccination followed MMR vaccine within 28 days at HMO A (aRR: 3.1; 95% CI: 1.5-6.4).

CONCLUSIONS

Varicella vaccine failure in children was not associated with asthma or the use of inhaled steroids, but with the use of oral steroids. Administration of varicella vaccine before the age of 15 months may be associated with a slightly increased risk of breakthrough disease. As currently recommended, varicella vaccination should not be administered for 28 days after MMR vaccination.

摘要

目的

水痘突破病例是指接种疫苗42天之后发生水痘疾病,这表明疫苗接种失败。在1996年一家日托中心的水痘暴发中,观察到接种疫苗的哮喘儿童发生突破病例的风险增加了7倍。最近的疫情调查也确定接种疫苗时的年龄是突破病例的一个潜在风险因素。我们评估了水痘突破病例与哮喘、类固醇、水痘疫苗接种年龄以及麻疹-腮腺炎-风疹(MMR)疫苗接种时间之间的关联。

方法

我们在美国两家健康维护组织(HMO,A和B)对1993年以后出生并在1999年之前接受随访的儿童进行了一项回顾性队列研究。信息来自自动疫苗接种记录、诊所记录、医院出院记录和药房记录。

结果

我们在HMO A和B分别接种水痘疫苗的80584名和8181名儿童中,确定了268例和97例突破病例。水痘突破病例与哮喘、任何时间开具的吸入性类固醇以及接种疫苗前开具的口服类固醇均无关联。在HMO A(调整相对风险[aRR]:2.4;95%置信区间[CI]:1.3 - 4.4)和HMO B(aRR:2.8;95% CI:1.0 - 7.8),在接种口服类固醇后的 immediately 3个月内发现水痘突破病例风险增加,在HMO A水痘疫苗在15个月龄之前接种时(aRR:1.4;95% CI:1.1 - 1.9),以及在HMO A水痘疫苗在MMR疫苗接种后28天内接种时(aRR:3.1;95% CI:1.5 - 6.4)。

结论

儿童水痘疫苗接种失败与哮喘或吸入性类固醇的使用无关,但与口服类固醇的使用有关。在15个月龄之前接种水痘疫苗可能与突破疾病的风险略有增加有关。按照目前的建议,在MMR疫苗接种后28天内不应接种水痘疫苗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验